» Articles » PMID: 21178761

Concomitant Extrahepatic Disease in Patients with Colorectal Liver Metastases: when is There a Place for Surgery?

Overview
Journal Ann Surg
Specialty General Surgery
Date 2010 Dec 24
PMID 21178761
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate the impact of the location of extrahepatic disease (EHD) on survival and to determine patient outcome in a consecutive series of patients with both intrahepatic and extrahepatic colorectal metastases treated by an oncosurgical approach, combining repeat surgery and chemotherapy.

Background: Although recognized as poor prognostic factor, concomitant EHD is no more considered an absolute contraindication to surgery in patients with colorectal liver metastases (CLM). However, the impact of the location of EHD on survival and the benefit in patient outcome is still diversely appreciated.

Methods: From 840 patients resected for CLM between 1990 and 2006, 186(22%) also had resectable EHD. Sequential surgery was routinely combined with perioperative chemotherapy. Survival was compared with that of patients without EHD, prognostic factors were identified, and a predictive model was designed to better select surgical candidates.

Results: Patients resected for CLM with concomitant EHD experienced a lower 5-year survival than those without EHD (28% vs 55%, P < 0.001). Five poor prognostic factors were identified at multivariate analysis: EHD-location other than lung metastases (5-year survival: 23% vs 33%, P = 0.02), EHD concomitant to CLM recurrence (14% vs 34%, P < 0.001), carcinoembryonic antigen level at least 10 ng/mL (16% vs 37%, P=0.02), at least 6 CLM(9% vs 32%, P = 0.02), and right colon cancer (P = 0.02). Five-year survival ranged from 64% (0 factors) to 0% (>3 factors). In the EHD group, patients with an EHD-recurrence experienced better outcomes when resected than those treated by chemotherapy alone (5-year survival: 38% vs 21%, P = 0.05).

Conclusion: Although sequential surgery is warranted for patients with 5 or less CLM with isolated lung metastases, low carcinoembryonic antigen levels,and no right colon primary tumor, it should be questioned in the presence of more than 3 of these prognostic factors.

Citing Articles

Clinical Prediction Models for Prognosis of Colorectal Liver Metastases: A Comprehensive Review of Regression-Based and Machine Learning Models.

Kokkinakis S, Ziogas I, Llaque Salazar J, Moris D, Tsoulfas G Cancers (Basel). 2024; 16(9).

PMID: 38730597 PMC: 11083016. DOI: 10.3390/cancers16091645.


Five-year survival post hepatectomy for colorectal liver metastases in a real-world Chinese cohort: Recurrence patterns and prediction for potential cure.

Su Y, Liu W, Yan X, Wang L, Liu M, Wang H Cancer Med. 2023; 12(8):9559-9569.

PMID: 36846977 PMC: 10166917. DOI: 10.1002/cam4.5732.


Oligometastatic Colorectal Cancer: A Review of Definitions and Patient Selection for Local Therapies.

Miller E, Hitchcock K, Romesser P J Gastrointest Cancer. 2023; 54(4):1116-1127.

PMID: 36652155 PMC: 10352468. DOI: 10.1007/s12029-022-00900-5.


Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancer.

Conde-Moreno A, Gonzalez-Del-Alba A, Lopez-Campos F, Lopez Lopez C, Requejo O, de Castro Carpeno J Clin Transl Oncol. 2022; 25(4):897-911.

PMID: 36525230 DOI: 10.1007/s12094-022-03019-y.


Assessing the Impact of Primary Tumour Location on Survival After Resection of Colorectal Liver Metastases: A Propensity Weighted Retrospective Cohort Study.

Borakati A, Froghi F, Shetye A, Fusai G, Davidson B, Mirnezami R World J Surg. 2022; 46(7):1734-1755.

PMID: 35325347 DOI: 10.1007/s00268-022-06514-z.